FDA approved Galafold under accelerated approval, paving the way for the launch of the first oral therapy to treat a subset of patients with the rare condition Fabry disease. Amicus priced Galafold at $315,000 per year.

CEO Heather Bresch gave a soliloquy on US health care during the second quarter call, saying ‘perverse incentives’ have created a system that ‘feeds on higher prices.’

The company reported a second quarter of organic sales growth, though revenues declined because of divestitures. Dermatology and Diversified Products segments continued to face challenges, and the company is working to respond to an FDA CRL for potential new dermatology product Duobrii.

Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.

Teva has been able to hold onto a roughly 85% share of the Copaxone 40 mg market, but expects pressure from generics will intensify in the second half of the year.